TG Therapeutics (NASDAQ:TGTX) Trading Up 7.9% – Should You Buy?

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) shot up 7.9% on Tuesday . The stock traded as high as $30.79 and last traded at $31.0560. 1,394,719 shares changed hands during trading, a decline of 30% from the average session volume of 1,992,616 shares. The stock had previously closed at $28.77.

Analysts Set New Price Targets

Several equities analysts have commented on TGTX shares. JPMorgan Chase & Co. dropped their price target on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Wall Street Zen cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. The Goldman Sachs Group raised their price objective on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

TG Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10. The company has a market capitalization of $5.09 billion, a PE ratio of 11.46 and a beta of 1.87. The company’s 50-day simple moving average is $29.50 and its 200-day simple moving average is $31.50.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The business had revenue of $192.57 million for the quarter, compared to analyst estimates of $192.15 million. During the same quarter last year, the company posted $0.15 EPS. TG Therapeutics’s quarterly revenue was up 78.0% on a year-over-year basis. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Johnson Financial Group Inc. purchased a new position in TG Therapeutics in the 2nd quarter valued at $25,000. Danske Bank A S purchased a new position in TG Therapeutics during the 3rd quarter worth $25,000. Optiver Holding B.V. lifted its stake in shares of TG Therapeutics by 3,485.7% in the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 732 shares during the period. Bessemer Group Inc. lifted its stake in shares of TG Therapeutics by 117.1% in the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 486 shares during the period. Finally, Salomon & Ludwin LLC purchased a new stake in shares of TG Therapeutics in the third quarter valued at about $34,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.